Report Overview

Canada DPP-IV Inhibitor therapeutics market size stood at around USD XX million in 2019 and is projected to reach USD xx million by 2028, exhibiting a CAGR of X.X% during the forecast period.

DPP IV inhibitors are a class of hypoglycaemic agents that block the enzyme named dipeptidyl peptidase IV. Dipeptidyl peptidase IV enzyme breaks down the proteins responsible for stimulating the insulin-producing cells that slow down gastric secretion. Proteins can activate insulin release and can control the blood sugar level if DPP IV is inhibited in our body. Moreover, DPP IV inhibitors restrict the formation of glucagon, a hormone that increases blood glucose level and thereby control the glucose levels in the body. DPP IV inhibitors are widely utilized as a treatment for type 2 diabetes.



Market Driving and Restraining Factors

The increasing prevalence of type 2 diabetes is a significant public health concern in Canada. According to the University of British Columbia, 29% of Canadians, nearly 11 million, live with diabetes or prediabetes. Diabetes is associated with many complications that include cardiovascular disease, nephropathy, retinopathy, and neuropathy. Thus, the factors mentioned above drive the DPP IV inhibitors market. However, the cost for DPP IV inhibitors is very high that might hinder the DPP IV inhibitors market.